The average sales growth rate of Peking University Medicine in recent three years is 5.45%, ranking first among all listed companies (1300/ 17 10) and 69th/90th in its pharmaceutical industry, with poor extension growth.
Earnings per share growth
In the past, the EPS growth rate of Peking University Pharmaceutical was-1.37%, ranking among all listed companies (997/ 17 10) and 60/90 in its pharmaceutical industry. The company's growth was reasonable.
Profitability index
The average profit growth rate of Peking University Medicine in recent three years is 3.44%, ranking among all listed companies (1084/ 17 10) and in its pharmaceutical industry (66/90). Poor profitability.
EPS stability
In the past, Peking University Pharmaceutical ranked EPS stability among all listed companies (227/ 17 10) and ranked 8/90 in its pharmaceutical industry. The company operates stably and well. Investment classification
During the three months from July to September, 2009, there were two research reports, of which 0 were rated as buying, 0 as overweight, 2 as neutral, 0 as underweight and 0 as selling.
The historical price-earnings ratio of Peking University Medicine is between 35 times-170 times, and the current price-earnings ratio is 1 10, and the value tends to be reasonable.
PE distribution map
In 2008, the company's PE ranked in the top 78.9% of all listed companies from low to high, which was in a seriously unreasonable position. In 2009, PE ranked in the top 6. 1% among all listed companies with profit forecasts, which was in a lower position, which was unanimously expected. 1. The company is mainly engaged in the research and development, production and sales of pharmaceutical raw materials and preparation products, and has become the most important pharmaceutical raw materials production and export enterprise in Southwest China and an important raw materials production base in China. Due to the large population in China, the market potential for healthy consumption of medicine is huge, and the market prospect will become an important part of expanding domestic demand, and the company will also benefit from it.
2. The corporate income tax of the Company from 2008 to 20 10 was levied at the reduced rate of 15%. The implementation of this preferential policy will have a positive impact on the company's net profit index.
3. Main financial indicators of the company in the first three quarters of 2009: earnings per share 0. 13 (yuan), net assets per share 1.95 (yuan), return on net assets 6.63%, and operating income 6 1032 167.77 (yuan) The net profit attributable to shareholders of listed companies was 33642747.78 yuan, up or down by 29.44438+07% year-on-year.
4. The CSRC approved the company to issue 42,872,365,438+065,438+0 yuan RMB ordinary shares to Beijing Peking University Medical Industry Group Co., Ltd. to purchase 90.63% equity of Chongqing Daxin Pharmaceutical Co., Ltd. held by Peking University Medical Industry Group. 1. It was in June of 20 14 that Peking University Pharmaceuticals entered the market value of10 billion, and planned to purchase 0/00% equity of Shenzhen Integrated Medical/kloc-0 for14.02 million yuan. After the resumption of trading in June 18, the share price of Peking University Pharmaceutical rose by nearly 28% in just 10 days, and its market value directly exceeded 10 billion from 8 billion.
2.2065438+In July 2004, Peking University Medicine (000788, Share Bar) announced that it would jointly invest with peking university health science center, Peking University Cancer Hospital, Peking University Medical Industry Fund and other parties to establish Peking University Medical Cancer Hospital Management Co., Ltd., the largest cancer specialist medical management group in China. From the birth of the concept of Peking University International Hospital in 2000 to the landing of Peking University Medical Industry Chain in 20 14, the growth of Peking University Medicine has become the epitome of China's medical reform in the past 14 years.